{"id":"https://openalex.org/W539813","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.14573","title":"Rash severity and dose in phase I dose escalation cetuximab (C225) trial","display_name":"Rash severity and dose in phase I dose escalation cetuximab (C225) trial","publication_year":2008,"publication_date":"2008-05-20","ids":{"openalex":"https://openalex.org/W539813","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.14573","mag":"539813"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2008.26.15_suppl.14573","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.14573","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.14573","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035562927","display_name":"Randeep S. Sangha","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. S. Sangha","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048614301","display_name":"Cheryl Ho","orcid":"https://orcid.org/0000-0002-5922-3984","observed_orcids":["https://orcid.org/0000-0002-5922-3984"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Ho","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059185125","display_name":"Laurel A. Beckett","orcid":"https://orcid.org/0000-0002-2418-9843","observed_orcids":["https://orcid.org/0000-0002-2418-9843"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Beckett","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109146676","display_name":"M. Tanaka","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Tanaka","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"D. H. Lau","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. H. Lau","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068073376","display_name":"Daniel Brian Eisen","orcid":"https://orcid.org/0000-0001-6741-3182","observed_orcids":["https://orcid.org/0000-0001-6741-3182"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. B. Eisen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010265482","display_name":"Philip C. Mack","orcid":"https://orcid.org/0000-0003-4750-3812","observed_orcids":["https://orcid.org/0000-0003-4750-3812"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. C. Mack","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018205931","display_name":"Rebekah A. Burich","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. A. Burich","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036091074","display_name":"David R. Gandara","orcid":"https://orcid.org/0000-0003-1784-048X","observed_orcids":["https://orcid.org/0000-0003-1784-048X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. R. Gandara","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5110112302","display_name":"Angela M. Davies","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. M. Davies","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":"15_suppl","first_page":"14573","last_page":"14573"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.7455999851226807,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.7455999851226807,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.20090000331401825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.006500000134110451,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.9959999918937683},{"id":"https://openalex.org/keywords/epidermal-growth-factor-receptor","display_name":"epidermal growth factor receptor","score":0.8539999723434448},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7590000033378601},{"id":"https://openalex.org/keywords/skin-rash","display_name":"rash","score":0.6430000066757202},{"id":"https://openalex.org/keywords/acneiform-rash","display_name":"acneiform rash","score":0.8769999742507935},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9120000004768372},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8429999947547913},{"id":"https://openalex.org/keywords/tumor-response","display_name":"tumor response","score":0.5440000295639038},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8270000219345093},{"id":"https://openalex.org/keywords/head-and-neck-cancer","display_name":"head and neck cancer","score":0.8289999961853027},{"id":"https://openalex.org/keywords/cholangiocarcinoma","display_name":"cholangiocarcinoma","score":0.9850000143051147},{"id":"https://openalex.org/keywords/anti-egfr-therapy","display_name":"anti-EGFR therapy","score":0.5270000100135803},{"id":"https://openalex.org/keywords/lymphopenia","display_name":"lymphopenia","score":0.47999998927116394}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9186256527900696},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.8398395776748657},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.7353091239929199},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.550764262676239},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5302566885948181},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.49487370252609253},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4692043662071228},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.25163477659225464},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.23012417554855347}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2008.26.15_suppl.14573","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.14573","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.14573","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1967210005","https://openalex.org/W2535405141","https://openalex.org/W2325412499","https://openalex.org/W2297856782","https://openalex.org/W1775605021","https://openalex.org/W2602954056","https://openalex.org/W2107692859","https://openalex.org/W2245406219","https://openalex.org/W1974705721","https://openalex.org/W4255134809"],"abstract_inverted_index":{"14573":[0],"Background:":[1],"C225":[2,26,53,71,111,335],"is":[3,16,37,343,352],"a":[4,60,263,277,304],"monoclonal":[5],"antibody":[6],"targeting":[7],"epidermal":[8],"growth":[9],"factor":[10],"receptor":[11],"(EGFR).":[12],"The":[13,225],"FDA-approved":[14],"dose":[15,41,67,215,227,285,354],"400":[17,72,79,336,340],"mg/m2":[18,73,80,337,341],"loading":[19,74,338],"with":[20,31,97,166,265,269,339,364],"weekly":[21,52,81],"maintenance":[22,342],"at":[23],"250":[24],"mg/m2.":[25],"efficacy":[27],"has":[28],"been":[29],"correlated":[30],"grade":[32,90],"of":[33,50,183,274,300,310,330,350,373],"skin":[34,57],"rash,":[35],"which":[36],"reported":[38],"to":[39,231],"be":[40,294],"dependent.":[42,286],"This":[43],"study":[44],"examined":[45],"the":[46,223,357],"safety":[47],"and":[48,55,75,137,154,188,190,248,267,288,327,345,360],"feasibility":[49],"escalating":[51],"doses,":[54],"evaluated":[56,125],"rash":[58,244,281,351,375],"as":[59],"surrogate":[61],"for":[62,112,159],"tumor":[63],"response.":[64],"Methods:":[65],"Four":[66],"levels":[68,329],"were":[69,157,170],"tested:":[70],"250,":[76],"300,":[77],"350,":[78],"maintenance.":[82],"Dose":[83],"limiting":[84],"toxicity":[85,108],"(DLT)":[86],"was":[87,124,217,229,257,283],"defined":[88],"as:":[89],"(Gr)":[91],"4":[92,102,114],"platelets,":[93],"Gr":[94,101,105,119,235,279],"3":[95,106,120,177,179],"platelets":[96],"bleeding,":[98],"febrile":[99],"neutropenia,":[100],"cutaneous":[103,107],"toxicity,":[104],"necessitating":[109],"holding":[110],">":[113],"weeks,":[115],"or":[116,381,384],"other":[117],"\u2265":[118,278],"non-hematologic":[121],"toxicity.":[122],"Rash":[123],"using":[126,356],"two":[127],"additional":[128],"validated":[129],"dermatology":[130],"methods:":[131],"global":[132],"acne":[133,138,289],"grading":[134,290],"scale":[135,291],"(GAGS)":[136],"lesion":[139],"counting":[140],"(Int":[141],"J":[142,146],"Derml":[143],"36:416\u201318,":[144],"1997;":[145],"Am":[147],"Acad":[148],"Derm":[149],"35:559\u201365,":[150],"1996).":[151],"Tumor":[152],"specimens":[153],"blood":[155],"samples":[156],"obtained":[158],"correlative":[160],"analyses.":[161],"Results:":[162],"Twenty-six":[163],"patients":[164],"(pts)":[165],"advanced":[167],"solid":[168],"tumors":[169],"treated,":[171],"including:":[172],"5":[173,191],"head":[174],"&":[175],"neck,":[176],"pancreas,":[178],"cholangiocarcinoma,":[180],"2":[181,212,280],"each":[182],"prostate,":[184],"breast,":[185,319],"colorectal,":[186],"lung,":[187],"esophagus,":[189],"others.":[192],"Characteristics:":[193],"Age":[194],"range":[195],"44\u201384,":[196],"median":[197],"60;":[198],"Gender:":[199],"19":[200],"M;":[201],"KPS":[202],"\u226580":[203],"=":[204],"15;":[205],"Prior":[206],"chemo":[207],"\u22641=":[208],"6;":[209],"Median":[210],"cycles":[211],"(1\u20138).":[213],"Planned":[214],"escalation":[216],"completed":[218],"without":[219],"DLTs":[220],"nor":[221],"reaching":[222],"MTD.":[224],"highest":[226],"level":[228],"expanded":[230],"17":[232],"pts":[233,275,302],"total.":[234],"3/4":[236],"toxicities":[237],"were:":[238],"lymphopenia":[239],"(2),":[240,242],"fatigue":[241],"acneiform":[243],"(1),":[245,247],"hypomagnesemia":[246],"elevated":[249],"GGT":[250],"(1).":[251],"In":[252,296],"22":[253],"evaluable":[254],"pts,":[255],"there":[256],"1":[258,299,309],"partial":[259],"response":[260,365],"(PR)":[261],"in":[262,366],"pt":[264],"cholangiocarinoma,":[266],"7":[268],"stable":[270],"disease":[271],"(SD).":[272],"65%":[273],"had":[276,303,312],"that":[282],"not":[284,353,362],"GAGS":[287],"analyses":[292],"will":[293],"described.":[295],"ongoing":[297],"analyses,":[298],"9":[301],"KRAS":[305],"mutation":[306],"(pancreas,":[307],"PD),":[308],"8":[311],"EGFR":[313,325,331],"amplification":[314],"by":[315],"FISH":[316],"(heavily":[317],"pre-treated":[318],"SD).":[320],"Additional":[321],"planned":[322],"correlatives":[323],"include":[324],"polymorphisms":[326],"tumor/plasma":[328],"ligands.":[332],"Conclusions:":[333],"1)":[334],"feasible":[344],"well":[346],"tolerated.":[347],"2)":[348],"Grade":[349],"dependent":[355],"CTCAE":[358],"v3.0":[359],"does":[361],"correlate":[363],"this":[367],"limited":[368],"cohort.":[369],"3)":[370],"Novel":[371],"methods":[372],"evaluating":[374],"are":[376],"required.":[377],"Author":[378],"Disclosure":[379],"Employment":[380],"Leadership":[382],"Consultant":[383],"Advisory":[385],"Role":[386],"Stock":[387],"Ownership":[388],"Honoraria":[389],"Research":[390],"Expert":[391],"Testimony":[392],"Other":[393],"Remuneration":[394],"OSI":[395],"Oncology":[396],"Bristol-Myers":[397,399],"Squibb":[398,400]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}